{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:19Z","timestamp":1794009079289,"version":"4.8.0"},"reference-count":44,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Cytomegalovirus (CMV) is widespread and mostly causes asymptomatic infections in immunocompetent hosts, but it may lead to severe and life-threatening diseases in immunocompromised individuals, such as transplant patients and congenitally infected children, representing a significant public health concern. Although there are no licensed CMV vaccines, the development of a CMV vaccine is considered a high priority due to its potential to reduce the burden associated with CMV-related complications, and several approaches are under investigation. The objective of this systematic review was to synthesize the evidence on various CMV vaccines currently under clinical development. Methods: According to the PRISMA guidelines (PROSPERO ID: CRD42024516601), a comprehensive literature search was conducted to identify all the randomized controlled trials that have evaluated the safety, immunogenicity, and efficacy of vaccine candidates compared to a placebo. A total of 26 studies were identified: 11 on transplant patients and 15 on healthy individuals. Results: Several vaccine candidates have shown encouraging results in terms of safety and specific immune responses, notably adjuvanted gB vaccines and DNA vaccines targeting gB and pp65. The results were divided into RCTs on healthy individuals and those on transplant recipients, because the CMV-specific immune response to a vaccine is complex and varies depending not only on the type of vaccine, but also on the immunological status of the individual. Conclusions: Challenges remain in achieving broad efficacy across diverse populations, particularly for immunocompromised patients. Thus, the present work seeks to support future decisions and guide further research in the development of an effective and widely available CMV vaccine.<\/jats:p>","DOI":"10.3390\/vaccines13010085","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T06:53:32Z","timestamp":1737442412000},"page":"85","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety, Immunogenicity, and Efficacy of Cytomegalovirus Vaccines: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-7486","authenticated-orcid":false,"given":"Manuela","family":"Chiavarini","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Florence, Viale GB Morgagni 48, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4959-867X","authenticated-orcid":false,"given":"Anita","family":"Genga","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Section of Hygiene, Preventive Medicine and Public Health, Polytechnic University of the Marche Region, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7274-9730","authenticated-orcid":false,"given":"Giorgia Maria","family":"Ricciotti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Section of Hygiene, Preventive Medicine and Public Health, Polytechnic University of the Marche Region, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello Mario","family":"D\u2019Errico","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Section of Hygiene, Preventive Medicine and Public Health, Polytechnic University of the Marche Region, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1495-0165","authenticated-orcid":false,"given":"Pamela","family":"Barbadoro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Section of Hygiene, Preventive Medicine and Public Health, Polytechnic University of the Marche Region, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/fvl.12.8","article-title":"The immune response to human CMV","volume":"7","author":"Diamond","year":"2012","journal-title":"Future Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41579-021-00610-y","article-title":"Infections at the maternal\u2013fetal interface: An overview of pathogenesis and defence","volume":"20","author":"Megli","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/CMR.13.1.83","article-title":"New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients","volume":"13","author":"Sia","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chen, S.J., Wang, S.C., and Chen, Y.C. (2019). Antiviral Agents as Therapeutic Strategies Against Cytomegalovirus Infections. Viruses, 12.","DOI":"10.3390\/v12010021"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2055-6640(20)30872-4","article-title":"Cytomegalovirus vaccines under clinical development","volume":"2","author":"Schleiss","year":"2016","journal-title":"J. Virus Erad."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(84)90930-9","article-title":"Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants","volume":"1","author":"Plotkin","year":"1984","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0264-410X(84)90088-4","article-title":"Cytomegalovirus vaccine: Persistence of humoral immunity following immunization of renal transplant candidates","volume":"2","author":"Sachs","year":"1984","journal-title":"Vaccine"},{"key":"ref_13","first-page":"81","article-title":"Cytomegalovirus vaccine trial in 400 renal transplant candidates","volume":"17","author":"Balfour","year":"1985","journal-title":"Transplant. Proc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-114-7-525","article-title":"Effect of Towne Live Virus-Vaccine On Cytomegalovirus Disease After Renal-Transplant\u2014A Controlled Trial","volume":"114","author":"Plotkin","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"ref_15","first-page":"1176","article-title":"Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients","volume":"58","author":"Plotkin","year":"1994","journal-title":"Transplantation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Boeckh","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_18","first-page":"100787","article-title":"A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients","volume":"33","author":"Ljungman","year":"2021","journal-title":"EClin. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_21","first-page":"1994","article-title":"A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant","volume":"109","author":"Nakamura","year":"2024","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/vim.2000.13.49","article-title":"Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin","volume":"13","author":"Drulak","year":"2000","journal-title":"Viral Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/339003","article-title":"Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults","volume":"185","author":"Bernstein","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine Prevention of Maternal Cytomegalovirus Infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/319680","article-title":"A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects","volume":"183","author":"Berencsi","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/infdis\/jiaa121","article-title":"A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus","volume":"225","author":"Schwendinger","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/503365","article-title":"A phase 1 study of 4 live, recombinant human cytomegalovirus Towne\/Toledo chimeric vaccines","volume":"193","author":"Heineman","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiz141","article-title":"Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMVSeronegative Subjects","volume":"220","author":"Adler","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Murata, S., Oshima, N., Iwasa, T., Fukao, Y., and Sawata, M. (2023). Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study. Antibodies, 12.","DOI":"10.3390\/antib12010022"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/cpdd.792","article-title":"Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and-Seropositive Healthy Subjects","volume":"9","author":"Bonate","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.vaccine.2023.12.019","article-title":"An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study","volume":"42","author":"Langley","year":"2024","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","article-title":"Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1, Randomized, Clinical Trial","volume":"230","author":"Fierro","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41423-024-01186-2","article-title":"Immune surveillance of cytomegalovirus in tissues","volume":"21","year":"2024","journal-title":"Cell Mol. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1469-0691.12449","article-title":"Cytomegalovirus vaccine: Phase II clinical trial results","volume":"20","author":"Rieder","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-016-0653-5","article-title":"Cytomegalovirus Vaccines: Current Status and Future Prospects","volume":"76","author":"Anderholm","year":"2016","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Scarpini, S., Morigi, F., Betti, L., Dondi, A., Biagi, C., and Lanari, M. (2021). Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice. Vaccines, 9.","DOI":"10.3390\/vaccines9060551"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Esposito, S., Chiopris, G., Messina, G., D\u2019Alvano, T., Perrone, S., and Principi, N. (2021). Prevention of Congenital Cytomegalovirus Infection with Vaccines: State of the Art. Vaccines, 9.","DOI":"10.3390\/vaccines9050523"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00043-19","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1586\/14760584.2015.989990","article-title":"Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation","volume":"14","author":"Nishihori","year":"2015","journal-title":"Expert Rev. Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/1\/85\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:30:52Z","timestamp":1759919452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/1\/85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["vaccines13010085"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13010085","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}